Insider Buying: Enovis (NYSE:ENOV) Insider Acquires $25,944.00 in Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert acquired 1,200 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the transaction, the insider directly owned 51,840 shares in the company, valued at $1,120,780.80. The trade was a 2.37% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Oliver Engert also recently made the following trade(s):

• On Monday, June 15th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was acquired at an average cost of $20.92 per share, for a total transaction of $20,920.00.
• On Wednesday, June 10th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was acquired at an average cost of $23.00 per share, for a total transaction of $23,000.00.
• On Monday, June 1st, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were purchased at an average cost of $22.22 per share, for a total transaction of $22,220.00.

Enovis Price Performance

ENOV opened at $20.83 on Thursday. Enovis Corporation has a 12-month low of $20.55 and a 12-month high of $36.82. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87. The business’s fifty day simple moving average is $23.94 and its 200-day simple moving average is $24.37. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -1.05 and a beta of 1.38.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. During the same quarter in the prior year, the company earned $0.81 EPS. The business’s revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts anticipate that Enovis Corporation will post 3.65 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ENOV. Evercore reissued an “outperform” rating and set a $36.00 price target on shares of Enovis in a research report on Friday, May 8th. Zacks Research downgraded Enovis from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 1st. BTIG Research reissued a “buy” rating and set a $39.00 price target on shares of Enovis in a research report on Friday, May 22nd. Wall Street Zen downgraded Enovis from a “buy” rating to a “hold” rating in a research report on Saturday, June 6th. Finally, Needham & Company LLC increased their price target on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $44.50.

Institutional Investors Weigh In On Enovis

Hedge funds have recently made changes to their positions in the stock. Arax Advisory Partners purchased a new stake in shares of Enovis during the 4th quarter worth $29,000. EverSource Wealth Advisors LLC lifted its stake in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Enovis by 353.5% during the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock worth $49,000 after purchasing an additional 1,446 shares during the last quarter. Danske Bank A S purchased a new stake in shares of Enovis during the 3rd quarter worth $64,000. Finally, iSAM Funds UK Ltd purchased a new stake in shares of Enovis during the 3rd quarter worth $80,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.